Fresenius, the prominent medical and hospital group based in Bad Homburg, has achieved notable success in the recent quarter, posting a revenue increase of 7% to 5.3 billion euros and an 8% rise in adjusted EBIT to 552 million euros.
Buoyed by its investment in Fresenius Medical Care and growth in its generic drug division, Kabi, the company has raised its 2024 forecasts, anticipating organic sales growth of 6-8% and an adjusted EBIT increase of 8-11%.
This upward revision reflects the company's strong operational performance, which showed a 9% rise in adjusted operating profit when excluding special effects. In contrast, Siemens Healthineers faced challenges despite achieving significant growth, highlighting the varying fortunes within the medical sector.
infobud.news is an AI-driven news aggregator that simplifies global news, offering customizable feeds in all languages for tailored insights into tech, finance, politics, and more. It provides precise, relevant news updates, overcoming conventional search tool limitations. Due to the diversity of news sources, it provides precise and relevant news updates, focusing entirely on the facts without influencing opinion. Read moreExpand
